| INTRODUCTION
Long QT syndrome (LQT) is a pro-arrhythmogenic condition that increases the risk of a unique life-threatening polymorphic ventricular tachycardia known as "torsades de pointes," and sudden cardiac death (SCD). Congenital LQTs are inherited disorders caused by mutations in cardiac conduction channels or associated proteins, and are estimated to affect 0.005% to 0.05% of the general population. 1 LQT is also accounted for by QT prolonging drugs, electrolyte abnormalities, 2 ischemic heart disease 3 or structural heart disease; a condition that is often referred to as acquired LQT. With the advent of genome sequencing it is evident that genetic variants with small effects also account for some, if not all, subclinical acquired LQTs that manifest themselves in the presence of additional precipitating factors. 4, 5 It has also been estimated that 10% to 36% of patients with LQT genotypes are silent mutation carriers. 6, 7 To this date 15 different types of congenital LQT have been characterized and account for about 80% of inherited long QT cases.
These correspond to mutations in genes encoding potassium channels, [8] [9] [10] [11] [12] [13] calcium channels, 14 calcium signaling proteins, [15] [16] [17] anchoring proteins, 18, 19 transport proteins, 20, 21 and voltage-gated sodium channels. 22, 23 Most of these genes have been established as casual genes for LQT based on linkage or segregation analysis, or in the case of KCNE2, CAV3, SNTA1 and CALM2 genes by association studies. The genetic cause of congenital LQT remains unknown in at least 20% of cases. 24 The SCN10A gene encodes the alpha subunit of a voltage-gated sodium channel (Na v 1.8), which is expressed in the peripheral nervous system, and also has low expression in atrial and ventricular cardiomyocytes and neurons of the heart. [25] [26] [27] [28] Genome-wide association studies implicated the SCN10A gene in cardiac conduction. [29] [30] [31] In addition, mutations in the SCN10A gene have been linked to cardiac arrhythmias such as Brugada syndrome, [32] [33] [34] [35] [36] atrial fibrillation [37] [38] [39] [40] and SCD.
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SCN10A influences cardiac conduction via 3 proposed mechanisms based on a multitude of in vitro and in vivo studies. 42 Given the expression of Na v 1.8 in cardiac myocytes, it can have direct effects on cellular physiology. 25, 26, 30 Alternatively, indirect effects could be mediated via modifying the expression of SCN5A gene, located immediately downstream of its 3 0 end. The presence of an enhancerbinding domain of SCN5A within the SCN10A gene, encompassing exons 17 and 18, supports this concept. [43] [44] [45] Lastly, SCN10A, which has robust expression in the cholinergic vagal neurons and dorsal root ganglia, has been associated with modulation of cardio-vagal input from the peripheral nervous system. 27, 46, 47 No prior studies attributed QT prolongation to mutations in
SCN10A.
In this study, we report a series of patients who were referred to our cardiovascular genetics clinic for genetic screening for prolonged QT associated with either syncope, pre-syncope, SCD, or AF and were found by whole-exome sequencing (WES) to have damaging mutations in the SCN10A gene.
| MATERIALS AND METHODS

| Study subjects
Patients were referred to the Yale Cardiovascular Genetics team for genetic screening of SCD and/or cardiac arrhythmias. The protocols were approved by the institutional review board at Yale University School of Medicine. Written consent to participate in the study and to undergo genetic sequencing was obtained from all patients.
Detailed clinical information, including laboratory data and clinical imaging were collected. Potential non-genetic causes for prolonged QT were excluded. Out of the 18 patients referred for prolonged QT, palpitation and syncope/pre-syncope, 2 were on QT prolonging medications and hence were excluded from the initial mutation burden analysis. Five out of the 16 patients had already undergone targeted panel genotyping for LQT in previous years with negative results.
Genomic DNA was extracted from peripheral blood leukocytes and sent for exome sequencing. Family history was obtained from the index cases, and pedigrees were constructed based on selfreported phenotypes. Family members were not available for segregation analysis. Thus, we proceeded with a mutation burden analysis.
| WES and targeted sequence capture
Genomic DNA was captured on exomes at the W.M. Keck Facility at
Yale University using Roche NimbleGen 2.1M Human Exome Array, as described earlier. 48 In brief, DNA libraries were prepared and sequenced on the Illumina Genome Analyzer (Illumina Inc, San Diego, CA, USA), followed by image analysis and base calling. Sequences were aligned against human reference genome (UCSC Genome Browser hg19) and processed using MAQ program SAMtools. SAMtools was also used for the single-nucleotide variant detection and filtering against the reference genome as described earlier. Filters were applied against published databases. A computer script was designed for variants annotation based on the novelty, conservation, tissue expression and their effect on protein function. They were considered non-conservative if the substituted amino acid was conserved in all species. Polyphen, SIFT and CADD scoring were used for in silico prediction of pathogenicity of the mutations. 49 Genetic intolerance score was calculated using Residual Variation Intolerance Score (RVIS). 50 We first screened for all variants in known LQT-associated genes Given that non-synonymous SCN10A mutations with allele frequencies as high as 1% have been associated with Brugada syndrome and AF, we screened the remaining subjects for SCN10A mutations using a less stringent frequency of <1%. The analysis revealed 2 additional missense mutations. One mutation leading to p.R14L amino acid substitution in SCN10A was identified in a 48-year-old woman who presented with syncope and LQT and had no identifiable mutation in known LQT genes. The p.R14L variant, which based on PolyPhen and SIFT is predicted to be damaging (Table 1) has an allele frequency of 0.19% in EXAC database and has been previously associated with AF and Brugada but not long QT ( Table 2 ). The second missense mutation in SCN10A resulted in p.R1268Q substitution and was identified in a subject with familial AF, long QT, pre-syncope and palpitations of no identifiable cause, who also had no identifiable mutation in known LQT genes. The p.R1268Q variant has an allele frequency of 0.18% in EXAC database (Table 1 ), but its disease association was not known. The variant was predicted to be damaging by SIFT only.
Conservation analysis showed that all of the substituted amino acids are evolutionarily highly conserved ( Figure 1B ). There was no clustering of the mutations observed, hence a genotype-phenotype correlation could not be established ( Figure 1B ). For instance, the p.
R1268Q variant is located in the cytoplasmic portion of the protein, while the p.R1259Q variant is in the transmembrane portion between the voltage-sensing domain and the channel-pore domain.
Interestingly, none of the above mutations were near the enhancer-binding domain of the SCN10A gene ( Figure 1A ). There was strong family history of arrhythmias and LQT among SCN10A mutation carriers ( Figure 2 ). Careful review of the pedigree suggests pleotropic effect of these mutations, resulting in trait that range from atrial fibrillation to supraventricular tachycardia, long QT and syncope with an inheritance that is consistent with an autosomal dominant pattern. First degree relatives were not available for genetic testing.
| SCN10A mutations among patients on QT prolonging medications
Two patients, who were taking QT prolonging medications also underwent exome sequencing. The first patient was a 59-year-old e All ECG intervals are reported in milliseconds.
f T-wave morphology, checked for T-wave alternans, and notched T-waves.
g Polyphen in silico prediction software.
h In silico prediction software.
i CADD score of more than 15 is considered pathogenic. Borderline elevated QTc interval is given in bold and high QTc interval is given in italics.
man with a complex medical history including hypertrophic cardiomyopathy (HCM), on metoclopramide who had QT prolongation, and was found to have a genetic variant in the SCN10A gene leading to p.
R485C substitution. Interestingly, he later developed persistent AF. He had also a non-conservative MYBPC3 mutation as the underlying cause of his HCM. The SCN10A p.R485C is a rare variant with an allele frequency of 7.0 × 10 −4 in the EXAC database, which is also predicted to be damaging.
The second patient was a 57-year-old woman, who presented with persistent AF and had been placed on Sotalol. Her QTc on this drug ranged from 459 to 615 milliseconds. Given the strong family history of arrhythmia and AF she underwent WES, which revealed a missense mutation in SCN10A gene leading to p.R209H substitution. There were no other mutations identified in known arrhythmia genes. The p.R209H is a rare variant with an allele frequency of 3.3 × 10 −5 in the EXAC database and is predicted to be damaging. Both substituted amino acids were highly conserved ( Figure 1A ) and none was located near the enhancer-binding domain of the SCN10A gene ( Figure 1B) . Moreover, the CADD scores for p.R485C and p.R209H were 34 and 33, respectively which suggest a very high likelihood of pathogenicity.
| Review of rare damaging SCN10A mutations in EXAC and mutation burden analysis
We queried the EXAC database for rare damaging mutations in the SCN10A gene. Out of the 60 706 total subjects, there were 303 damaging mutations at an allele frequency of less <1:100 000 ( Figure 3 ).
Mutation burden analysis (Table S1 ) using the EXAC database as control showed an odds ratio of 90.9 for having prolonged QT if the patient harbors a rare and deleterious SCN10A mutation (95% confidence interval of 31.4-263.2, P-value < .0001).
In a second analysis using an allele frequency of <1:100 2 more variants in the SCN10A gene were identified in our patient cohort.
Additionally, out of the 60 706 total subjects in the EXAC database, there were 574 damaging mutations at an allele frequency <1:100.
These included missense (n = 501), nonsense (n = 32), splice (n = 17),
(B) FIGURE 1 Nav1.8 voltage-gated sodium channel encoding SCN10A gene domains, long QT-associated mutations and conservation analysis. A, SCN10A gene is comprised of 27 exons located on the short arm of chromosome 3. The enhancer-binding domain encompasses exons 17, 18 and the intronic region in between. The mutations are labeled along the gene with the corresponding dbSNP (rs) number when available. B, Several of the mutations fall within the transmembrane alpha helical domains (G810fs, R1259Q, and R1268Q), the R14L is in the Nterminal domain, and the P1877fs is in the C-terminal domain. The 2 mutations in the patients who were on QT prolonging medications are labeled in orange, the R209H in proximity to the voltage-sensing domain and R485C within the channel-modulation domain. All the mutation occurred at evolutionarily conserved site. [Color figure can be viewed at wileyonlinelibrary.com] frameshift (n = 15), deletion (n = 8), and insertion (n = 1). Mutation burden analysis at this allele frequency showed an odds ratio of 4.9
for having prolonged QT if the patient harbors a deleterious SCN10A mutation (95% confidence interval of 1.7-14.2, P-value = .0047; Table S1 ). Interestingly, SCN10A's RVIS score of −1.32 places this gene among the 4.74% most intolerant genes. Taken together, our analyses provide strong statistical evidence for association between SCN10A mutations and long QT trait.
| Systematic literature review of all reported SCN10A mutations and available ECG characteristics
In our review of the published literature we found 46 different SCN10A mutations reported. The available clinical and ECG data are summarized in Table 2 . Interestingly, heterozygous SCN10A mutations causing p.F385C, p.I1225T, p.N1328K, and p.N1715T amino acid substitutions were detected in 4 independent patients with QT prolongation. All 4 variants had been reported in independent publications, hence they lacked the power to establish association between SCN10A mutations and QT prolongation.
The subject with the deleterious p.F385C SCN10A variant is reported as a 65-year-old man with a history of SCD, Brugada syndrome, and a QTc of 464 milliseconds ( Table 2) .
One of the 2 subjects with symptomatic Brugada syndrome and p.I1225T variants had been reported to have a prolonged QTc of 525 milliseconds ( Table 2 ).
The third deleterious SCN10A mutation had been reported in a 68-year-old man with syncope and a prolonged QTc of 450 milliseconds. He had a novel missense mutation in SCN10A that substituted a highly conserved amino acid (p.N1328K).
The fourth reported deleterious SCN10A mutation substitutes a highly conserved amino acid (p.N1715T) with a rare allele frequency of 8.1 × 10 −4 in the EXAC database. This mutation had been identified in a 65-year-old man with pre-syncope and palpitations, In addition, there has been report of 6 different SCN10A mutations in 6 subjects with borderline prolonged QTc, resulting in p.R14L, p.
W189R, p.R844H, p.S1337T, p.G1406D, and p.G1662S amino acid substitutions ( Table 2 ). All of these mutations substituted highly conserved amino acids and were predicted to be damaging. Of note, there have been 6 patients with the p.R14L variant, 4 patients with the p.
G1662S variant and 2 patients with the p.R844H variant reported and only 1 from each group has had borderline prolonged QTc (Table 2) .
| DISCUSSION
Voltage-gated sodium channels (Na v ) conduct inward sodium currents that are regulated by the transmembrane potential. These channels are composed of the pore forming or α-subunit, and a β regulatory subunit.
The α-subunit possesses a voltage-sensing domain, a pore domain with a filter selective for sodium ions, an activation gate, and an inactivation gate. 55 There are 9 different Na v s identified in humans with different tissue distribution and functionality based on the α-subunit. 55 The α-subunits of Na v 1.1 to Na v 1.9 are encoded by 9 different genes.
Gain-of-function mutations in SCN5A have been previously implicated in congenital LQT type 3. 56 The SCN5A gene encodes Na v 1.5, which is the most abundant voltage-gated sodium channel in cardiac tissue. Na v 1.5 is responsible for the depolarization phase of the cardiac action potential, characterized by rapid inward sodium current that is quickly inactivated by the inactivation gate. 57 Congenital LQT type 3 mutations cause a gain-of-function in Na v 1.5 due to failure of the inactivation gate to terminate the influx of sodium at the appropriate time. Hence, sodium entry slowly continues during the subsequent phases of the action potential and results in prolonged repolarization. 58 This is in contrast to Brugada-associated mutations in SCN5A that cause loss-of-function via premature closure of Na v 1.5 channel without effect on the QT interval. 59 An overlap syndrome of long QT and Brugada has also been described as some SCN5A genotypes can cause features of both syndromes. 60 In parallel, SCN10A mutations have been strongly associated with Brugada syndrome and other cardiac conduction abnormalities in humans. In fact, up to 10% of Brugada cases are attributed to SCN10A mutations. 34 A recent fine-mapping study implicated the SCN5A-SCN10A locus in QT prolongation. 61 in vitro studies have shown that the Na v 1.8 contributes to late cardiac sodium current and displays marked differences in gating compared with Na v 1.5. 26 While the enhancer hypothesis offered a mechanism whereby polymorphisms in SCN10A could contribute to SCN5A expression levels, 45 the majority of the arrhythmiaassociated SCN10A mutations fall far from the enhancer-binding domain. However, a direct effect through the sympathetic nervous system is another plausible mechanism. Although Nav1.8 has low expression in cardiomyocytes, its expression levels are high in intra-cardiac ganglia and neurons. 27, 62 Loss of Nav1.8 current had low effect on cardiomyocyte conduction. 27, 62 However, Nav1.8 blockade significantly reduces the sodium current and firing frequency of intra-cardiac neurons. 27 Similarly, Nav1.8 channel blockade in cardiac ganglionated plexi has been shown to suppress cardiac conduction and atrial fibrillation inducibility. 46 Accordingly, left cardiac sympathetic neuron denervation (LCSD) has been successfully used to treat LQT. 63, 64 In our study, we observed a remarkably high prevalence of deleterious SCN10A mutations in patients with prolonged QT, an association that has not been made before. All the observed mutations affected the amino acid sequence of Nav1. R1259Q, and p.P1877fs) in SCN10A provided a strong signal of association with LQT, the subsequent mutations were present at higher allele frequencies. For instance, the p.R1268Q variant was present at an allele frequency of 0.18% that is high compared with the prevalence of LQT.
However, the same mutation had been associated with Brugada syndrome, 34, 36 which is also a rare disease. 65 Similarly, the p.R14L variant with an allele frequency of 0.19% had been previously associated with Brugada syndrome. 34, 38, 39 We speculate that these are diseasecontributing variants that are not sufficient to independently cause disease, which explains their pleotropic effects and incomplete penetrance.
The 2 variants (p.R209H, p.R485C) identified in the 2 patients who were on QT prolonging medications are also most likely not sufficient to cause LQT and require the contribution of environmental factors such as QT prolonging drugs. Although mutations in known LQT genes account for about 80% of LQT cases, our study was enriched for patients who had previously undergone targeted genotyping panels (5 of 16 patients) with negative results for LQT gene mutations. This has resulted in the lower yield for mutations in known LQT genes in our WES and likely higher SCN10A mutation rate compared with the general population.
Of interest is the prior association between SCN10A mutations and unexplained nocturnal SCD. 41 Although the SCD had been attributed to a possible underlying Brugada syndrome, the current findings suggest that LQT induced torsades could be another mechanism of SCD in patients harboring SCN10A mutations. Overall, these findings are of great significance to the study of cardiac electrophysiology and prevention of fatal arrhythmias in at-risk subjects.
| CONCLUSION AND FUTURE PROSPECTS
To this date there is no definitive therapy available for LQT, therefore, screening and early detection of prolonged QT remains a central approach for risk stratification and primary prevention against fatal arrhythmias in affected subjects and their extended families. Hence, it is imperative to identify all genetic culprits in abnormal cardiac repolarization and long QT. Strikingly, the genetic cause in congenital LQT remains elusive in about 20% of inherited cases, while many of the acquired LQTs are also accounted for by predisposing genetic mutations.
Our study implicates SCN10A mutations as an underlying cause of LQT, adding to the list of genes that should be screened for in patients with prolonged QT. The presence of frameshift mutations, which result in premature stop codon and potentially nonsensemediated decay, suggest that the disease mechanism is due to lossof-function of the encoded protein. In addition, the common association with AF suggests that SCN10A may represent a unique subtype of LQT genes.
Our findings advance the identification of genetic causes of LQT and improve the capability of screening in individuals at risk. Further investigations into genotype-phenotype correlation may improve our ability to predict the development of isolated atrial fibrillation, Brugada syndrome, LQT or combination thereof in SCN10A mutation carriers. In addition, future investigations are necessary to examine the co-expression and interaction of SCN10A with SCN5A in regulation of sodium current in cardiomyocytes.
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